Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes
- PMID: 40355587
- PMCID: PMC12069179
- DOI: 10.1007/s12672-025-02192-0
Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes
Abstract
Aim: The prevalence of BRCA1/2 pathogenic variants among Turkish breast cancer (BC) patients is not well-characterized. We specifically examine the age at onset and cancer sub-types concerning BRCA1/2 mutation status, focusing on patients with no family history of breast or ovarian cancer.
Methods: Peripheral blood samples were collected from 3184 BC patients applied to the Istanbul University Oncology Institute. Genetic testing for BRCA1/2 mutations was conducted using the Illumina MiSeq® platform, with variant classification performed according to ACMG criteria.
Results: Among the 3184 patients, 2764 (86.8%) were BRCA1/2-, while 247 (7.8%) were BRCA1 + and 173 (5.4%) were BRCA2 + . The mean age at BC onset was significantly lower in BRCA1 + (39.73 years) and BRCA2 + (41.07 years) patients compared to BRCA1/2- patients (43.17 years, p < 0.001). Among patients with no family history, HER2 positive cases had a significantly higher mean age at onset than Triple-Negative Breast Cancer(TNBC) cases (41.78 years vs. 40.44 years, p = 0.017).
Conclusions: This study highlights the strong association between BRCA1/2 + mutations and earlier BC onset, particularly in patients with no family history of breast or ovarian cancer in Türkiye.
Keywords: BRCA1/2 mutations; Breast cancer; HER2 positive; Triple-negative breast cancer (TNBC); Turkish population.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Breast Cancer Res. 2012 Nov 2;14(6):R142. doi: 10.1186/bcr3347. Breast Cancer Res. 2012. PMID: 23116406 Free PMC article.
-
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.BMC Cancer. 2016 Aug 23;16(1):673. doi: 10.1186/s12885-016-2698-y. BMC Cancer. 2016. PMID: 27553291 Free PMC article.
-
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8. J Transl Med. 2019. PMID: 30975216 Free PMC article.
-
Genetic Tests for Breast and Ovarian Cancer [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. PMID: 29319983 Free Books & Documents. Review.
-
Germline Mutations in Triple-Negative Breast Cancer.Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24. Breast Care (Basel). 2017. PMID: 28611536 Free PMC article. Review.
References
-
- Society AC. Breast cancer risk and prevention
-
- Valencia OM, et al. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 2017;152(6):589–94. - PubMed
-
- Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007;8(3):255–67. - PubMed
-
- Institute NC. Cancer Stat Facts: Female Breast Cancer. 2024.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous